María Natalia Gandur Quiroga: Key Advances in Prostate, Kidney, and Bladder Cancers Unveiled at GU24

María Natalia Gandur Quiroga shared a post on LinkedIn:

“Key Advances in Prostate, Kidney, and Bladder Cancers Unveiled at GU24:
Dr Neeraj Agarwal and Dr. Todd Morgan share groundbreaking findings from the 2024 ASCO Genitourinary Cancers Symposium GU24.
Tune in to reshape clinical practice!

Highlight Summary:

Groundbreaking results from CONTACT-02, KEYNOTE-564, and CheckMate-67T lead the charge in genitourinary oncology breakthroughs.
CONTACT02 trial highlights the efficacy of cabozantinib and atezolizumab in metastatic castration-resistant prostate cancer, showing significant improvements in progression-free survival.
KEYNOTE564 presents compelling evidence for adjuvant pembrolizumab post-surgery in clear cell renal cell carcinoma, marking a first in improved overall survival in adjuvant therapy for RCC.
EV302 trial underlines the superiority of enfortumab vedotin and pembrolizumab combination over standard chemotherapy in untreated, advanced urothelial carcinoma, potentially setting a new standard of care.
CheckMate67T introduces subcutaneous nivolumab as a practical alternative to intravenous administration in metastatic renal cell carcinoma, promising to enhance healthcare efficiency.

Clinical Practice Impact:
These studies set new benchmarks in treatment and diagnosis, pushing the envelope for personalized, evidence-based patient care.
Innovations in treatment administration methods are poised to reduce treatment burden and streamline healthcare delivery.

Global Engagement:
The symposium’s success, with over 5,200 attendees from more than 70 countries, underscores the global commitment to advancing science and transforming patient care in the field of genitourinary oncology.”

View additional information.
Source: Dra. María Natalia Gandur Quiroga/LinkedIn